Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study


Phase 2 Study of the 20 mL Biologic Lung Volume Reduction (BLVR) System in Patients With Homogeneous or Upper Lobe Predominant Emphysema




The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in patients with homogeneous emphysema. Patients with upper lobe predominant emphysema initially screened for earlier Phase 2 studies but not enrolled before study enrollment closed are also eligible for participation.

Study Status: Completed


Condition Intervention Phase
Homogeneous Emphysema Biological: Biologic Lung Volume Reduction Phase 2

Verified by Aeris Therapeutics October, 2011

Sponsored by: Aeris Therapeutics
Information provided by: Aeris Therapeutics identifier: NCT00630227

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation, Pulmonary Allergy & Critical Care Medicine
Cleveland, Ohio 44195
United States

Mark Gotfried, MD., Principal Investigator
Mark Dransfield, MD., Principal Investigator
Gerard Criner, MD., Principal Investigator
William Leeds, DO., Principal Investigator
Mark Krasna, MD., Principal Investigator
Thomas Gildea, MD., Principal Investigator
Sanjiv Tewari, MD., Principal Investigator
Geoffrey McLennan, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site